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Dermatitis
Nilesh Morar1, William O.C.M. Cookson1, John I. Harper2 and Miriam F. Moffatt1
Atopic dermatitis (AD) results from strong genetic and environmental interactions. AD shows genetic linkage to
Chromosome 1q21. This region contains the epidermal differentiation complex (EDC), which consists of genes
that form essential components of epidermal surfaces. Filaggrin (FLG) is one of these. Mutations in FLG/(R501X
and 2282del4) are reported to be strongly associated with AD and to influence asthma accompanying AD. We
investigated these effects in families recruited through a child with severe AD. We genotyped two panels of
families, totalling 426, containing 990 affected and unaffected children. We found significant associations with
AD (P¼ 0.0001), asthma (P¼ 0.006), and atopy (P¼ 0.002). The FLG mutations were present in 26.7% of patients
with AD, but were also present in 14.4% of children without AD. They were weakly associated with disease
severity. The variants were not independently associated with asthma. The overall LOD score for genetic linkage
of markers to the region was 3.57. This fell to 2.03 after accounting for the FLG mutations, indicating the
presence of other genetic variants influencing AD at this locus. Our results provide further confirmation of the
importance of mutations in FLG and the skin barrier in AD pathogenesis. The results indicate that investigations
of other genes within the EDC should be undertaken.
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INTRODUCTION
Atopic dermatitis (AD) is strongly genetic (Larsen et al., 1986;
Schultz Larsen, 1993), and the discovery of genes underlying
the disease offers the promise of better understanding of its
pathogenesis. Genome screens have identified areas of
genetic linkage to AD on Chromosomes 1q21 (Cookson
et al., 2001), 3q21 (Lee et al., 2000; Bradley et al., 2002),
3p24–22 (Bradley et al., 2002), and 17q25 (Cookson et al.,
2001). The composite phenotype of AD and asthma
combined has also shown significant linkage to Chromosome
20p (Cookson et al., 2001). The 1q21, 3q21, 17q25, 20p, and
5q31 loci overlap with psoriasis loci (Cookson et al., 2001;
Bowcock and Cookson, 2004).
Chromosome 1q21 is of particular interest as it harbors the
epidermal differentiation complex (EDC). This is a group of
genes and gene families that are physically contained within
1.8 Mb of DNA and are expressed during terminal differ-
entiation of the human epidermis. Gene families within the
EDC include the S100 calcium binding proteins, small
proline-rich proteins, and late expressed cornified envelope
proteins (Mischke et al., 1996; Marshall et al., 2001).
Members of the peptidoglycan recognition protein family
(PGLYRP3 and PGLYRP4) are also encoded within the region.
Single copy genes in the EDC include trichohyalin, repetin,
involucrin, filaggrin (FLG), and loricrin.
Monogenetic disorders have successfully been used to
identify genes in AD. Mutations in SPINK5 cause Netherton
syndrome in which atopy is a universal accompaniment.
Variants in SPINK5 provide susceptibility to AD (Walley
et al., 2001; Kato et al., 2003; Nishio et al., 2003; Kusunoki
et al., 2005), though no association was seen in one study
(Folster-Holst et al., 2005). These associations with SPINK5
mutations and variants support the hypothesis that a
dysfunctional skin barrier predisposes to AD (Cookson,
2004).
Another recessive cutaneous disorder, ichthyosis vulgaris,
has recently been shown to be caused by loss-of-function
homozygous or compound heterozygous mutations, R501X
and 2282del4, in exon three of the FLG gene (Smith et al.,
2006). Approximately 8% of patients with AD have clinical
features of ichthyosis vulgaris (Tay et al., 1999). Immunohis-
tochemistry, ELISA (Seguchi et al., 1996), and microarray
(Sugiura et al., 2005) studies have previously shown
decreased protein levels and decreased RNA expression of
FLG in AD skin.
Profilaggrin is found in the keratohyalin granules in the
stratum granulosum. Profilaggrin is dephosphorylated and
proteolytically cleaved to FLG during terminal differentiation
of the granular cells. FLG then aggregates the keratin
filaments, which collapse the granular cells into anuclear
squames. The cytoskeleton is then crosslinked by trans-
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glutaminases to form the cornified cell envelope of the
stratum corneum (Markova et al., 1993) and the outermost
barrier of the skin. FLG is therefore an excellent candidate
gene for AD.
The group that identified the two FLG mutations under-
lying ichthyosis vulgaris subsequently found them to be
strongly associated with AD and asthma in populations of
European origin (Palmer et al., 2006). Their results indicated
that the – variants were carried by B9% of people of
European origin (Palmer et al., 2006). In collaboration with
this group, investigators also found these loss-of-function
variants to be associated with AD and allergic sensitizations
in a German cohort and trios (Weidinger et al., 2006) and
with adult AD (Barker et al., 2006). In the German samples
the FLG mutations were associated with extrinsic AD
characterized by raised IgE and allergic sensitizations and
not the intrinsic form of the disease (Weidinger et al., 2006).
Another German group also independently found FLG
mutations to be strongly associated with AD, although only
the R501X mutation was tested in their panel of trios (Ruether
et al., 2006). A significant association with FLG null
mutations with AD has also been shown recently by a
German group that investigated families and population-
based cases and controls (Marenholz et al., 2006).
These results all indicate that mutations in FLG are a
significant risk factor for AD. It claims, however that they are
also an independent risk factor for AD-associated asthma
(Palmer et al., 2006; Weidinger et al., 2006) and that 50% or
more of children with moderate to severe AD and 20% of all
cases of asthma associated with AD carry FLG mutations
(Irvine and McLean, 2006) suggest additional hypotheses that
do require investigation.
We have therefore investigated the two FLG variants in
panels of families recruited through children with AD from a
tertiary referral center. These children represent the most
severe end of the disease spectrum and form an important
clinical group who are often resistant to maximal therapy.
Approximately 60% of these children also suffer from asthma.
These families contained affected as well as unaffected
children, allowing us to examine the effect of FLG mutations
in normal and diseased subjects sharing a common genetic
and environmental background.
RESULTS
In the ECZ1 panel, 254 children had AD, with a mean age of
6.89 years (7SEM 0.270), 124 (48.8%) were male subjects,
139 (55.6%) had asthma, and the mean total serum IgE in
children with AD was 438.6 IU/L (95% confidence interval
(CI)¼ 328.5–585.5). In the replication panel MRCE, 403
children had AD. The children’s mean age was 6.7 years
(7SEM 0.21). 223 (55.3%) were male subjects and 233
(57.8%) had asthma. Their mean total IgE was 521.5 IU/L
(95% CI¼328.5–585.5). In all 18.9% had mild disease,
52.1% had moderate disease, and 29% had severe disease in
the ECZ1 panel. In the MRCE panel, 15% were mild, 46.2%
were moderate and 38.8% were severe. All children however
were on maximal therapy when recruited. With regard to
ethnicity in the ECZ1 panel, the three major groups were
Caucasian (90%), Asian (1%), and mixed race (4.3%). In the
MRCE panel, 69% were Caucasian, 14% South Asian, and
8% were of mixed race.
Hardy–Weinberg equilibrium was observed for both
markers. We initially tested the two family panels indepen-
dently for association with AD, before combining the panels
in subsequent tests. We similarly investigated the two
mutations separately (to determine if they had differing
effects on disease susceptibility), as well as testing for
association with a combined genotype for both mutations.
As association between AD and FLG mutations is not in
doubt, uncorrected P-values for association testing are given
throughout.
Significant associations were seen in affected children in
the ECZ1 panel for the single-nucleotide polymorphism
R501X with AD (T 24, NT 10, and P¼ 0.02) and for
2282del4 for AD (T 39, NT 13, and P¼0.0003), asthma
(T29, NT10, and P¼0.002), and atopy (T 37, NT 13, and
P¼0.0007). For the combined genotype associations were
seen for AD (T 64, NT 33, and P¼ 0.002), asthma (T 41, NT
24, and P¼ 0.04), and atopy (T 58, NT 33, and P¼0.009)
using the transmission disequilibrium test.
In the MRCE panel significant associations were seen with
R501X and AD (T 55, NT 21, and P¼0.0001), asthma (T 43,
NT19, and P¼ 0.002), and atopy (T 57, NT 27, and
P¼0.001) and for 2282del4 for AD (T 30, NT 16, and
P¼0.04), asthma (T 26, NT 12, and P¼0.02), and atopy (T
35, NT20, and P¼ 0.04). For the combined genotype
associations were seen for AD (T 84, NT 53, and P¼0.008)
and atopy (T88, NT 64, and P¼0.052).
Associations were also seen in the combined family panels
for R501X with AD (P¼0.0001), asthma (P¼ 0.0008), and
atopy (P¼ 0.0002). For the 2282del4 marker associations
were seen with AD (P¼0.0001), asthma (P¼ 0.0002), and
atopy (P¼0.0001) and for the combined genotype for AD
(P¼0.0001), asthma (P¼ 0.006), and atopy (P¼0.002),
(Table 1). The results were not different in terms of trans-
mission frequencies when only Caucasians were examined.
In order to investigate the penetrance of the mutations,
transmission ratios were also examined in unaffected children
(Table 1). Both variants were common in the unaffected
children, confirming that the mutations are not exclusively
associated with AD.
The distribution of FLG variants was then examined in
children with and without AD. The FLG null variants were
present in 26.7% of children with AD and in 14.1 % of
unaffected children. We therefore calculated the penetrance
of AD in FLG null carriers to be 78.7% in these subjects.
We investigated the risk of disease in affected and
unaffected children using logistic regression analysis. Age
and sex did not significantly predict the presence of AD in the
logistic model, perhaps reflecting the narrow age range and
sex ratios of children in our study. The exclusion of non-
Caucasians did not affect the estimates of risk of disease
either. Dominant or recessive models did not fit the data
better than an additive model.
The results indicated that the combined genotype was
associated with an increased risk (odds ratio (OR) 2.03, 95%
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CI¼1.5–2.8) for developing disease (Table 2). Calculation of
the Pseudo-R2 for the regression model (Nagelkerke 1991),
indicated that the FLG mutations contributed 3.2% to the
variation of the presence of AD in these children. This
suggested that other genetic and environmental factors, in
addition to the FLG mutations, were necessary for the
development of disease in these subjects.
We then examined the relationship of the FLG mutations
to AD separately in atopic and non-atopic children. Logistic
regression analysis showed the FLG variants to be associated
with extrinsic AD characterized by atopy (OR 2.28, 95%
CI¼1.46–3.56), (Table 3). When non-atopic children were
examined, there were no significant associations with AD.
We next performed a logistic regression to determine the
relationship of the compound mutation genotype to asthma in
the absence of AD (Table 4). There were 58 asthmatics and
234 non-asthmatics amongst the children without AD. This
gave 96% power to detect a gene with an OR of 2 for disease
for each risk allele with a¼0.1 and 93% power with a¼0.05
(Purcell et al., 2003). The mutations were not significantly
associated with asthma in these children (OR 1.28, 95%
CI¼0.64–2.55, and P¼0.49).
Including parents in the analyses, there were 146
asthmatics and 706 non-asthmatics amongst individuals
without AD. This gave 99.98% power to detect a gene with
an OR of 2 for each disease allele with a¼0.05, and 98%
power to detect a gene with an OR of 1.5 at a¼ 0.05. The
mutations also did not show evidence for association to
asthma in this full sample (OR 0.94, 95% CI¼ 0.59–1.48, and
P¼0.78).
The FLG mutations were significantly associated with the
severity of AD (measured by the criteria of Rajka and
Langeland (1989)), with P¼ 0.007 in a linear regression
model. The adjusted R2 was however 0.8%, indicating a
minor effect on the severity of the illness in these subjects.
Calculation of variance in severity owing to FLG mutations
within the quantitative transmission disequilibrium test
program gave a similar result of 0.9%.
We next examined if the FLG mutations accounted for the
previously reported linkage signal between the EDC micro-
satellite marker D1S498 and AD (Cookson et al., 2001). We
reanalysed the data for the previously reported highly linked
marker D1S498 (Cookson et al., 2001) with the compound
FLG genotype in the ECZ1 panel of families. We used the
LAMP program (Li et al., 2005) which maximizes the
evidence for association across all genetic models, and
provides tests for the presence of additional linked variants in
addition to the mutation under study. For AD, the evidence
for linkage to the markers was a total LOD score of 3.57 (3
degrees of freedom (df)), P¼0.0009. The FLG only LOD
Table 1. Results for affected and unaffected children in the combined family panel for FLG mutations R501X,
2282del4, and the combined genotype
SNP
AD affected
T:NT1 (P)
Asthma affected
T:NT (P)
Atopy affected
T:NT (P)
AD unaffected
T:NT (P)
Asthma unaffected
T:NT (P)
Atopy unaffected
T:NT (P)
FLG501X 79:31 (0.0001) 55:25 (0.0008) 76:36 (0.0002) 21:30 (NS) 44:34 (NS) 23:22 (NS)
FLG2282del4 69:29 (0.0001) 55:22 (0.0002) 72:33 (0.0001) 18:21 (NS) 30:30 (NS) 19:12 (NS)
Combined 148:86 (0.0001) 108:71 (0.006) 146:97 (0.002) 59:36 (NS) 75:73 (NS) 48:35 (NS)
1FLG, filaggrin; T, number of transmitted alleles; NS, not significant; NT, number of untransmitted alleles.
Table 2. Logistic regression analysis of association
between FLG mutations and AD in all children
P-value OR 95% CI
FLG501X 0.001 2.55 (1.50–4.34)
FLG2282del4 0.004 1.93 (1.23–3.03)
Compound genotype o0.001 2.03 (1.46–2.81)
AD, atopic dermatitis; CI, confidence interval; FLG, filaggrin; OR, odds
ratio.
Table 3. Logistic regression analysis of association
between FLG mutations (compound genotype) with
AD in atopic and non-atopic children
P-value OR 95% CI
Atopic children o0.001 2.28 (1.46–3.56)
Non-atopic children 0.45 1.29 (0.67–2.49)
AD, atopic dermatitis; CI, confidence interval; FLG, filaggrin; OR, odds
ratio.
Table 4. Contingency table for logistic regression
analysis of genetic predictors of association between
FLG mutations (compound genotype) and asthma in
individuals without AD
11 12 22 P-value OR 95% CI
Full sample, no asthma 589 111 6
Full sample, asthma 122 24 0 0.78 0.94 (059–1.48)
Children only, no asthma 202 29 3
Children only, asthma 47 11 0 0.49 1.28 (0.64–2.55)
AD, atopic dermatitis; CI, confidence interval; FLG, filaggrin; OR, odds
ratio; 11, wild-type allele; 12, heterozygous for either mutation; 22,
homozygous for either mutation or heterozygous for both mutations.
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score was 1.54 and the residual evidence for linkage after the
FLG mutations were taken into account was a LOD score of
2.03 (2 df), P¼0.009, indicating the presence of other
genetic variants influencing AD in proximity to D1S498
and the EDC. These variants may include as yet undiscovered
mutations in FLG itself, or polymorphisms in other epidermal
genes from the locus.
DISCUSSION
The results support prior studies in indicating that the FLG
mutations have an important influence on susceptibility to
AD (Barker et al., 2006; Marenholz et al., 2006; Palmer et al.,
2006; Ruether et al., 2006; Weidinger et al., 2006). Our
multivariate analyses confirm that the variants are strongly
but incompletely penetrant (Palmer et al., 2006).
Our results indicate that the FLG mutations did not have
an independent effect on asthma, at least in our children with
severe AD and their families. FLG is not expressed in the lung
mucosa, and the suggestion that a predisposition to asthma
may result from bystander allergies secondary to a permeable
skin (Hudson, 2006) represents a departure from current
understanding of asthma pathogenesis that requires further
investigation.
We found a higher frequency of FLG variants in unaffected
siblings from our family panels than previously reported
population estimates (Palmer et al., 2006). This is attributable
to the relatedness of these individuals to their siblings with
AD. Although ORs calculated in families are not directly
comparable to case–control studies, the risk of AD conferred
by FLG mutations in children with AD and their unselected
siblings appeared lower than might be expected from
previous reports of ORs ranging from 2.73 to 13.4 (Barker
et al., 2006; Marenholz et al., 2006; Palmer et al., 2006;
Ruether et al., 2006; Weidinger et al., 2006). In addition, our
allele transmission frequency of 63% for AD for the
combined genotype, was lower than previous family studies
(Marenholz et al., 2006; 68%; Weidinger et al., 2006; 73%)).
The reason for the apparently reduced risk in our subjects
is not clear. Some random differences between population
samples are to be expected in the study of any complex
genetic disease. The use of unselected siblings as controls
implies that we have studied the effect of FLG mutations in
individuals that share a common environment and
genetic background to affected children, providing a level
of control for these factors. Occult population admixture
may also confound estimations of risk, and a proportion of
families in our study were of South Asian origin. We found
that exclusion of these subjects did not alter our estimates of
risk or our observed transmission ratios to affected indivi-
duals. The use of family-based association testing has
provided an additional level of control for the effects of
admixture.
Differences in disease risk between studies could also be
accounted for by variation in disease spectrum. It may be
relevant that we have studied young children with severe AD
presenting to a tertiary referral center. In the context of health
care in the UK, tertiary referral is usually an indicator of
previous therapeutic failure. The therapy-resistant children in
our study may therefore have had AD that was driven by a
different balance of risk factors to population-based cases.
The observation that FLG mutations are extremely high-risk
factors for patients with persistent adult disease (Barker et al.,
2006) is also consistent with an underlying heterogeneity of
the disorder.
Both FLG variants that we tested are largely confined to
Europeans, and they have been found to be absent in non-
European populations of African and Asian origin (Palmer
et al., 2006). A third loss-of-function variant in FLG has
recently been identified, which highlights the variability of
this gene (Sandilands et al., 2006), but no common mutations
have yet been identified in non-Caucasian populations.
Population based studies have shown a 2-fold higher
prevalence of AD in black Caribbean children compared to
Caucasians children born in London (Williams et al., 1995).
A similar AD prevalence has been reported when black
infants of West Indian origin were compared to Caucasians
living in London (Davis et al., 1961). Further studies are
required to identify the role of this gene in other ethnicities
and the extent to which AD may be genetically hetero-
geneous in such populations.
Our results suggest that the FLG mutations are not solely
responsible for the significant genetic linkage of AD to the
EDC region on Chromosome 1q21 reported previously in the
ECZ1 panel (Cookson et al., 2001). The genes of the EDC are
expressed late during terminal differentiation and maturation
of keratinocytes. Genes from the EDC have been associated
with other cutaneous Mendelian disorders, including Voh-
winkel’s syndrome (Maestrini et al., 1996), and other genes in
the epidermal barrier have been shown to contribute to
atopic disease (Walley et al., 2001).
Many of the EDC genes may be candidates for AD by
virtue of their function and location. For instance, involucrin,
loricrin, and small proline-rich proteins encode structural
proteins that with trans-glutaminase mediate cross linking
resulting in the formation of the cornified cell envelope
(Roop, 1995). The S100 proteins are a multigene family of
low molecular weight calcium-binding proteins that have a
wide variety of functions that regulate the epidermal response
to tissue injury, inflammation, and disease (Kerkhoff et al.,
1999). They are increased in response to a variety of skin
stresses such as tape stripping and UV exposure (Gebhardt
et al., 2002). Interestingly in a microarray study of adult AD
patients versus controls S100A2, S100A7, S100A8, and
S100A9 levels were all found to be upregulated whereas
the cornified envelope genes loricrin and FLG were down-
regulated (Sugiura et al., 2005).
Additionally, peptidoglycan recognition proteins 3 and 4
(PGLYRP3 and PGLYRP4) are members of a family of innate
immunity pattern recognition proteins and are bactericidal
against Gram-positive bacteria. Several single-nucleotide
polymorphisms in the PGLYRP3-PGLYRP4 locus have
recently been reported to show association with psoriasis in
a family based analysis using the transmission disequilibrium
test (Sun et al., 2006). More than one-third of AD suscept-
ibility loci map to psoriasis linkage peaks (Cookson et al.,
2001; Bowcock and Cookson, 2004) suggesting that these
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two cutaneous conditions share genes or gene complexes that
are specific to cutaneous barrier defences and immunity.
The presence of numerous candidate genes in addition to
FLG within the EDC suggests that further investigation of this
complex locus may identify other genetic variants with effects
on a spectrum of dermatological disorders.
MATERIALS AND METHODS
Families were recruited from the Dermatology clinics at the Great
Ormond Street Hospital for Children, through a child or children
with active AD. A physician-administered questionnaire was
completed for each individual. The questionnaire included the
modified Hanifin and Rajka diagnostic criteria for AD defined by the
UK Working party (Williams et al., 1994a, b) and questions based on
the American Thoracic Society’s questionnaire for asthma and
allergic rhinitis. Each family was examined for evidence of AD by a
physician. Children lacking signs of disease were classified as
unaffected. The severity of eczema was assessed using the scoring
system of Rajka and Langeland (1989), which categorizes patients
into mild (3.0–4.0), moderate (4.5–7.5), or severe (8.0–9.0) disease on
the basis of surface area involvement, continuity of disease, and
nocturnal pruritus (Rajka and Langeland, 1989). Asthma was defined
on the basis of the questionnaire answers and a previous physician
diagnosis as described previously (Cox et al., 1998). Skin prick tests
(Dome-Hollister-Stier, Spokane, WA) were carried out on all
individuals for a range of allergens including: house dust mite
(Dermatophagoides pteronyssinus), Timothy Grass (Phleum
pratense), mould (Alternaria alternata), cat dander (Felis domesticus),
egg white and cow’s milk.
Total IgE and specific IgE (to the same panel of allergens) was
measured by a fluorescent enzyme immunoassay (Pharmacia CAP
system, Pharmacia, Uppsala, Sweden). A raised total serum IgE was
taken to be greater than 100 kU/L. Atopy was defined as: (i) the
presence of a positive skin prick test response 3 mm or greater than
the negative control, (ii) a positive specific IgE, (iii) raised total serum
IgE, or (iv) any combination of these features.
Initially DNA samples from a panel of 148 nuclear families of
northern European origin were examined, the ECZ1 panel. ECZ1 has
350 siblings and 245 sibpairs. The same families had been used
previously in an AD genome screen (Cookson et al., 2001). For the
purposes of replication, a second eczema panel, the MRC-E eczema
panel comprising of 278 families, 634 siblings, and 470 sibpairs was
used. Approval for the studies was obtained through the University
of Oxford and Great Ormond Street Hospital Ethics Committees.
Participants gave their full written informed consent. The investiga-
tions were conducted according to the Declaration of Helsinki
Principles.
Genotyping for R501X was performed using a Taqman-based
allelic discrimination assay (Applied Biosystems, CA). Primers and 6-
6-carboxy-fluorescein and VIC-labelled probes were genotyped
following standard protocols for the Applied Biosystems 7,300
sequence detection system. Primers and probes used were identical
to those previously published (Palmer et al., 2006).
The 2282del4 mutation was genotyped by sizing a 6-carboxy-
fluorescein-labelled PCR product on an Applied Biosystems 3,730
DNA sequencer. The wild-type allele was 199 bp and the 2282del4
allele was 195 bp. Primers DEL4F2 and DEL4R1 (Palmer et al., 2006)
with 0.05 U/ml AmpliTaq Gold DNA polymerase, 1X buffer, 200 mM
dNTP, and 1.5 mM MgCl2 were used in 10 ml PCR reactions. The
cycling conditions were: 941C (12 minutes), one cycle; 941C
(15 seconds), 581C (30 seconds), and 721C (45 seconds), 30 cycles;
and a final 721C (5 minutes). PCR fragments were sized against a
ROX-500 size marker using standard protocols from Applied
Biosystems.
Genotyping was performed blind to the phenotype and genotypes
were double checked by two independent investigators (NM and
MFM). Hardy–Weinberg equilibrium was tested by using the w2-
goodness-of-fit test. Family-based association analysis was carried
out using the transmission disequilibrium test and quantitative
transmission disequilibrium test (Spielman et al., 1993; Abecasis
et al., 2000) to examine the transmission rates of marker alleles from
parents to offspring for the phenotypes AD, asthma, and total log IgE.
Logistic regression analysis of predictors of AD and asthma was
performed with SPSS version 14.0. Genotypes were coded as 0 (1 1
homozygous for wild-type allele), 1 (1 2 heterozygous for mutation),
and 2 (2 2 homozygous for mutant allele). Dominant models were
encoded as 0, 1, and 1 and recessive models were encoded as 0, 0,
and 1. Age and sex were also tested for effects in the models.
The status of a residual linkage signal after the FLG mutations
were taken into account was investigated using the LAMP program
(Li et al., 2005). Association and linkage was tested to the compound
FLG mutation genotype in the ECZ1 panel of families, with D1S498
used as a framework marker as instructed (http://www.sph.umich.
edu/csg/abecasis/LAMP/).
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